Haemophilia and Bone Loss - PHILEOS Study

Who May Qualify: - Healthy Volunteers : - Healthy men aged between 20 to 60 years old - Haemophilic Patients: - Haemophilia A and B patients, irrespective of the disease form (mild, moderate, severe with or without prophylaxis) - Haemophilic patients aged between 20 to 60 years old - Severe Haemophilia A patients with prophylaxis : last factor VIII injection more than 48 to 120 hours (depending on on the prophylactic treatment) prior blood sampling dedicated to the this research - Severe Haemophilia B patients : last factor IX injection more than 5 to 21 days (depending on the prophylactic treatment) prior blood sampling dedicated to the this research Who Should NOT Join This Trial: - Healthy Volunteers: - History of disease known to influence bone metabolism (hyperthyroidism, hyperparathyroidism, hypercorticism, hypogonadism, diseases that require long-term use of corticoids, …) - Past or present treatment with any osteoporotic medication other than Vit D or Ca++ - Presence of two total hip prostheses - HIV documented infection - HCV documented infection (in progress or cured) at cirrhotic stage - Haemophilic Patients: - Haemophilic patients with current or history of inhibitor anti-fVIII or anti-fIX (\>5 Bethesda Units) - Treatment with HEMLIBRA (Emicizumab). Unless it is possible to use a result of thrombin generation prior to this treatment and achieved with a residual rate not greater than or equal to 5%. - History of disease known to influence bone metabolism and not related to haemophilia (hyperthyroidism, hyperparathyroidism, hypercorticism, hypogonadism, diseases that require long-term use of corticoids, …) - Past or present treatment with any anti-osteoporotic medication other than Vit D or Ca++ - Presence of two total hip prostheses - HIV documented infection - HCV documented infection (in progress or cured) at cirrhotic stage Always talk to your doctor about whether this trial is right for you.